Form EFFECT iBio, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Chardan Comments on iBio, Inc. (IBIO)
June 25, 2025 7:58 AM EDTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $5.00 price target on iBio, Inc. (NASDAQ: IBIO)
The analyst comments "iBio has announced its third program to address obesity, an amylin agonist antibody, that's part of its collaboration with AstralBio (private). This amylin receptor agonist antibody has shown to decrease food intake in a mouse model of obesity by 60%, comparable to the 67% food intake reduction observed with a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide. Amylin is a 37 amino acid pancreatic peptide hormone secreted by the pancreas... More
